

REMARKS

Reconsideration and re-examination are respectfully requested.

At the outset, Applicants' Representative notes that the Office Action Summary indicates that this Office Action is non-final (status box 2b) is checked), but that the Office Action at page 5 indicates that this Office Action was made final. Applicants' Representative has presumed that this Office Action was made final, but in the event this presumption is incorrect, asks that the Examiner process this Office Action Response as a Response to a non-final Office Action.

Claims 1, 11, and 13 remain in this application. Claim 1 has been amended to recite that AR-LBD is androgen receptor ligand binding domain. This amendment is supported, for example, in the specification at page 2, lines 14-15. Claim 1 has also been amended to indicate that the AR-LBD ligand is dihydrotestosterone. This amendment is supported throughout the application. No new matter is believed to be added.

Claim Objections

Claim 1 stands objected to as reciting "AR-LBD" without defining it for a first time. Claim 1 has been amended to recite "androgen receptor ligand binding domain (AR-LBD)" and withdrawal of this objection is respectfully requested.

35 U.S.C. 112, first paragraph

Claims 1, 11, and 13 stand rejected as purportedly failing to comply with the enablement requirement. Claim 1, as amended, is directed to a crystal of an androgen receptor ligand binding domain (AR-LBD) consisting of amino acids 13 through 258 of SEQ ID NO:1 complexed with an AR-LBD ligand that is dihydrotestosterone, and it is submitted that the specification enables one of skill in the art to make and use the subject matter of amended claim 1 (as well as claims 11 and 13 which depend from claim 1). Accordingly, withdrawal of this rejection is respectfully requested.


CONCLUSION

In view of the foregoing amendments and remarks, allowance of the application is respectfully requested. The Examiner is invited to contact the undersigned if there are any questions concerning the prosecution of this application.

The Commissioner is authorized to charge Deposit Account 19-3880 (Bristol-Myers Squibb Company) for any requisite fees due or to credit any overpayment.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-4091



Paul D. Golian
Attorney for Applicants
Reg. No. 42,591

Date: January 28, 2004